PMID- 23126502
OWN - NLM
STAT- MEDLINE
DCOM- 20130321
LR  - 20161125
IS  - 1365-3083 (Electronic)
IS  - 0300-9475 (Linking)
VI  - 77
IP  - 2
DP  - 2013 Feb
TI  - 1,25-dihydroxyvitamin D3 inhibits nuclear factor kappa B activation by 
      stabilizing inhibitor IkappaBalpha via mRNA stability and reduced phosphorylation in 
      passively sensitized human airway smooth muscle cells.
PG  - 109-16
LID - 10.1111/sji.12006 [doi]
AB  - Excessive activation of nuclear transcription factor-kappaB (NF-kappaB) is involved in 
      human airway smooth muscle cells (HASMCs) activities in asthma. We investigated 
      the effects of 1,25 - dihydroxyvitamin D3 [1,25 - (OH) 2D3] on the NF- kappaB 
      signaling pathway in passively sensitized HASMCs and the molecular mechanisms 
      involved. HASMCs were treated with either healthy controls' serum, asthma 
      patients' serum or pretreated with 1,25 - (OH) 2D3 prior to treatment with 
      asthmatics' serum. At 1 h after serum treatment: electrophoretic mobility shift 
      assay (EMSA) was used to detect NF-kappaB DNA binding activity; immunocytochemical 
      staining was used to observe the nuclear translocation of NF-kappaB p65; Western 
      blots were used for NF-kappaB p65, IkappaBalpha, and phospho-IkappaBalpha protein levels and the 
      nuclear translocation of NF-kappaB p65; real-time quantitative PCR was used for NF-kappaB 
      p65 and IkappaBalpha mRNA expressions; and actinomycin D treatment was used to determine 
      IkappaBalpha mRNA stability. Our major findings were: (1) 1,25 - (OH) 2D3 significantly 
      reduced asthma serum passively sensitized HASMCs NF-kappaB DNA binding activity and 
      inhibited the nuclear translocation of NF-kappaB p65; (2) 1,25 - (OH) 2D3 increased 
      the stability of IkappaBalpha mRNA with reduced IkappaBalpha phosphorylation in asthma serum 
      passively sensitized HASMCs and significantly increased IkappaBalpha expression in these 
      HASMCs. Inhibiting NF-kappaB signalling with 1,25 - dihydroxyvitamin D3 may be a 
      therapeutic approach for controlling HASMC-related remodelling in asthma.
CI  - (c) 2012 The Authors. Scandinavian Journal of Immunology (c) 2012 Blackwell 
      Publishing Ltd.
FAU - Song, Y
AU  - Song Y
AD  - Department of Pulmonary and Critical Care Medicine, Fuzhou General Hospital of 
      Nanjing Military Command, Dongfang Hospital, Xiamen University, Fuzhou, China.
FAU - Hong, J
AU  - Hong J
FAU - Liu, D
AU  - Liu D
FAU - Lin, Q
AU  - Lin Q
FAU - Lai, G
AU  - Lai G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Scand J Immunol
JT  - Scandinavian journal of immunology
JID - 0323767
RN  - 0 (I-kappa B Proteins)
RN  - 0 (NF-kappa B)
RN  - 0 (NFKBIA protein, human)
RN  - 0 (dihydroxy-vitamin D3)
RN  - 139874-52-5 (NF-KappaB Inhibitor alpha)
RN  - 1406-16-2 (Vitamin D)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Active Transport, Cell Nucleus
MH  - Adult
MH  - Asthma/genetics/immunology/metabolism
MH  - Cell Line
MH  - Cell Nucleus/metabolism
MH  - DNA/metabolism
MH  - Enzyme Activation/drug effects
MH  - Female
MH  - Humans
MH  - I-kappa B Proteins/*genetics/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Myocytes, Smooth Muscle/*drug effects/*metabolism
MH  - NF-KappaB Inhibitor alpha
MH  - NF-kappa B/*metabolism
MH  - Phosphorylation/drug effects
MH  - Protein Binding
MH  - RNA Stability/drug effects
MH  - Vitamin D/*analogs & derivatives/pharmacology
MH  - Young Adult
EDAT- 2012/11/07 06:00
MHDA- 2013/03/22 06:00
CRDT- 2012/11/07 06:00
PHST- 2012/07/16 00:00 [received]
PHST- 2012/10/10 00:00 [accepted]
PHST- 2012/11/07 06:00 [entrez]
PHST- 2012/11/07 06:00 [pubmed]
PHST- 2013/03/22 06:00 [medline]
AID - 10.1111/sji.12006 [doi]
PST - ppublish
SO  - Scand J Immunol. 2013 Feb;77(2):109-16. doi: 10.1111/sji.12006.